662 results on '"Lokhorst, Henk M"'
Search Results
2. Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma:Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial
3. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial
4. Illegitimate WNT Signaling Promotes Proliferation of Multiple Myeloma Cells
5. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
6. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
7. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
8. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
9. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
10. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
11. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
12. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
13. Discovery, Development, and Mechanisms of Action of the Human CD38 Antibody Daratumumab
14. Supplementary Figure 1 from T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells
15. Supplementary Figure 2 from T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells
16. Data from T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells
17. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System
18. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
19. Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment
20. Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement
21. Supplementary Figure Legends from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
22. Supplementary Data from Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells
23. Supplementary Figure 2 from Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells
24. Supplementary Figure 3 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
25. Supplementary Figure 2 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
26. Supplementary Figure 3 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
27. Supplementary Figure 1 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
28. Supplementary Figure 4 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
29. Supplemental Data from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
30. Supplementary Figure Legend from Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells
31. Supplementary Figure 1 from Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells
32. Supplementary Figure 6 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
33. Supplementary Figure 3 from Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells
34. Supplementary Figure 5 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
35. How I treat plasma cell leukemia
36. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma
37. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
38. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
39. Supplement to: Targeting CD38 with daratumumab monotherapy in multiple myeloma.
40. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
41. Treatment of relapsed and refractory multiple myeloma in the era of novel agents
42. Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program
43. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
44. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
45. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
46. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
47. Rituximab Treatment before Reduced-Intensity Conditioning Transplantation Associates with a Decreased Incidence of Extensive Chronic GVHD
48. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma
49. Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years
50. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.